⌘K
t
On 20 February 2023, e-therapeutics plc announced that its Chief Executive Officer, Mr Ali Mortazavi, notified the company of a transfer of 50,941,666 Ordinary Shares for nil consideration. These shares moved from TS Capital/JIM Nominees Limited to WH Ireland/SEI Investments (Europe), with Mr Mortazavi's total shareholding remaining unchanged at 50,941,666 Ordinary Shares, representing 8.75% of the Company's total issued share capital.
| Date | 20 Feb 2023 |
| Time | 10:19:51 |
| Category | Director/PDMR dealings |
| ID | 4472Q |
e-therapeutics plc
("e-therapeutics" or the "Company")
Director/PDMR Shareholding
London, UK, 20 February 2023 - e-therapeutics plc (AIM: ETX; OTCQX; ETXPF), a company integrating computational power and biological data to discover life-transforming RNAi medicines, announces that Mr Ali Mortazavi, the Company's Chief Executive Officer, has notified the Company of the transfer of 50,941,666 Ordinary Shares for nil consideration from TS Capital/JIM Nominees Limited to WH Ireland/SEI Investments (Europe).
Mr Mortazavi's shareholding is unchanged at 50,941,666 Ordinary Shares, representing 8.75% of the Company's total issued share capital.
The notification below, made in accordance with the requirements of the EU Market Abuse Regulation, provides further details:
|
1
|
Details of the person discharging managerial responsibilities / person closely associated
|
||||
|
a)
|
Name |
Ali Mortazavi |
|||
|
2
|
Reason for the notification Transfer to new Nominee
|
||||
|
a)
|
Position/status |
Chief Executive Officer |
|||
|
b)
|
Initial notification /Amendment
|
Initial notification |
|||
|
3
|
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
|
||||
|
a)
|
Name
|
e-therapeutics plc |
|||
|
b)
|
LEI
|
21380049RHSSJXWKYT18 |
|||
|
4
|
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
|
||||
|
a)
|
Description of the financial instrument, type of instrument |
Ordinary Shares of 0.1 pence each |
|||
|
|
|
||||
|
Identification code |
ISIN: GB00B2823H99 |
||||
|
|
|
||||
|
b)
|
Nature of the transaction
|
Transfer of shares between broker accounts. No change in beneficial ownership. |
|||
|
c)
|
Price(s) and volume(s) |
|
|
|
|
|
|
|
Price |
Volume |
|
|
|
|
|
Nil |
50,941,666 |
|
|
|
|
|
|
|
|
|
|
d)
|
Aggregated information |
N/A - single transaction |
|||
|
|
|
||||
|
- Aggregated volume |
|
||||
|
|
|
||||
|
- Price |
|
||||
|
|
|
||||
|
e)
|
Date of the transaction |
20 February 2023 |
|||
|
f)
|
Place of the transaction
|
Outside a trading venue |
|||
Enquiries:
|
e-therapeutics plc |
|
|
Ali Mortazavi, CEO James Chandler, VP IR & Communications
|
Tel: +44 (0)20 4551 8888 www.etherapeutics.co.uk |
|
|
|
|
SP Angel Corporate Finance LLP |
Tel: +44(0)20 3470 0470 |
|
Nominated Adviser and Broker |
|
|
Matthew Johnson/Harry Davies-Ball (Corporate Finance) |
|
|
Vadim Alexandre/Rob Rees (Corporate Broking) |
|
About e-therapeutics plc www.etherapeutics.co.uk
e-therapeutics plc ("ETX") integrates computational power and biology information to discover life-transforming RNAi medicines. The Company's technology uses computation to capture and model human biology, identify novel targets, and develop RNAi medicines against those targets that can be rapidly progressed to the clinic.
ETX's proprietary Computational Biology Platform enables the generation and analysis of biological network models, providing a novel and mechanistic approach to drug discovery that explicitly considers the true complexity of biology and makes more reliable predictions from large complex data sets and ETX's proprietary hepatocyte knowledgebase - the world's most comprehensive and integrated hepatocyte-centric data and information resource. The Company generates, prioritises and tests millions of hypotheses in silico to identify better therapeutic targets with higher confidence.
ETX's proprietary RNAi Platform enables the targeted delivery to hepatocytes in the liver and the specific silencing of novel disease-associated genes, identified by ETX's Computational Biology Platform. The focus on hepatocytes offers the opportunity to work across a wide variety of diseases. The liver is a highly metabolically active organ which performs a key role in many biological processes and vital functions crucial for human health. ETX's GalNAc-siRNA constructs have demonstrated compelling in vivo performance in terms of depth of gene silencing and duration of action.
ETX is progressing a pipeline of first-in-class pre-clinical RNAi candidates in several therapeutic areas including haematology, cardiovascular disease and non-alcoholic steatohepatitis ("NASH"). ETX has also partnered with biopharma companies such as Novo Nordisk, Galapagos NV and iTeos Therapeutics using its computational network biology approach across a diverse range of drug discovery projects.
The Company is based in London, UK and listed on the Alternative Investment Market of the London Stock Exchange ("AIM"), with ticker symbol ETX. e-therapeutics is also traded on the OTCQX Best Market (OTCQX) in the United States, under ticker symbol ETXPF.